CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin:: Similarities yet differences

被引：39

作者：

Takahashi, H

Wilkinson, GR

Padrini, R

Echizen, H

机构：

[1] Meiji Pharmaceut Univ, Dept Pharmacotherapy, Tokyo 2048588, Japan

[2] Vanderbilt Univ, Div Clin Pharmacol, Sch Med, Nashville, TN USA

[3] Univ Padua, Dept Pharmacol & Anesthesiol, Padua, Italy

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2004年 / 75卷 / 05期

关键词：

D O I：

10.1016/j.clpt.2004.01.007

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：376 / 380

页数：5

共 28 条

[21] Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes [J].

Takahashi, H ;

Kashima, T ;

Nomizo, Y ;

Muramoto, N ;

Shimizu, T ;

Nasu, K ;

Kubota, T ;

Kimura, S ;

Echizen, H .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (05) :519-528

[22] 5′-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients [J].

Takahashi, H ;

Ieiri, I ;

Wilkinson, GR ;

Mayo, G ;

Kashima, T ;

Kimura, S ;

Otsubo, K ;

Echizen, H .

BLOOD, 2004, 103 (08) :3055-3057

[23] Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin:: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes [J].

Takahashi, H ;

Kashima, T ;

Nomoto, S ;

Iwade, K ;

Tainaka, H ;

Shimizu, T ;

Nomizo, Y ;

Muramoto, N ;

Kimura, S ;

Echizen, H .

PHARMACOGENETICS, 1998, 8 (05) :365-373

[24] Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients [J].

Takahashi, H ;

Wilkinson, GR ;

Caraco, Y ;

Muszkat, M ;

Kim, RB ;

Kashima, T ;

Kimura, S ;

Echizen, H .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (03) :253-263

[25]

Thijssen HH, 2000, DRUG METAB DISPOS, V28, P1284

[26] Acenocoumarol pharmacokinetics in relation to cytochrome P4502C9 genotype [J].

Thijssen, HHW ;

Ritzen, B .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 74 (01) :61-68

[27] Altered pharmacokinetics and excessive hypotensive effect of candesartan in a patient with the CYP2C9*1/*3 genotype [J].

Uchida, S ;

Watanabe, H ;

Nishio, S ;

Hashimoto, H ;

Yamazaki, K ;

Hayashi, H ;

Ohashi, K .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 74 (05) :505-508

[28] Genetic and environmental risk factors for oral anticoagulant overdose [J].

Verstuyft, C ;

Robert, A ;

Morin, S ;

Loriot, MA ;

Flahault, A ;

Beaune, P ;

Funck-Brentano, C ;

Jaillon, P ;

Becquemont, L .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 58 (11) :739-745

← 1 2 3 →